USA – FDA issues three guidances to expand cancer clinical trial eligibility

The US Food and Drug Administration’s (FDA) has issued a trio of draft guidance documents that aim to promote greater participation and diversity in...

France – FDA guidance calls for testing all alcohol-based products for methanol

The US Food and Drug Administration (FDA) issued final guidance to assist manufacturers and compounders in testing alcohol products (ethanol and isopropyl) for methanol....

USA – FDA finalizes guidance on considerations for evaluating drug’s benefits and risks

The US Food and Drug Administration (FDA) has finalized guidance that clarifies how the benefits and risks of a drug or biologic factored into...

USA – FDA establishes advisory committee for genetic metabolic disease treatments

The Genetic Metabolic Diseases Advisory Committee will advise the FDA on products used for the diagnosis, prevention and treatment of genetic metabolic diseases under...

USA – FDA proposes updated medtech RWE guidance

The US Food and Drug Administration (FDA) has updated it’s guidance on how real-world data (RWD) can be used to provide real-world evidence (RWE)...

USA – FDA finalizes guidances on RWD in regulatory submissions, assessing registries

The US Food and Drug Administration (FDA) on Thursday finalized two guidances that detail how sponsors can leverage and submit real-world data (RWD) in...

USA – Stakeholders concerned with FDA’s definition of labeling in PDURS guidance

Stakeholders want the US Food and Drug Administration (FDA) to narrow its scope of what it considers labeling in a draft guidance for prescription...

USA – FDA proposes master control trial guidance that goes beyond COVID-19

The US Food and Drug Administration (FDA) this week published a draft guidance on the use of master protocols in clinical trials of drugs...

Canada – Notice – Implementation of ICH E19: A selective approach to safety data...

Health Canada, as an official member to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), is committed to...
Guidance Agenda: Guidance Documents CBER is Planning to Publish During Calendar Year 2020

USA – CBER chief on remote work, CRISPR-Cas9, and rare disease gene therapy accelerated...

The use of CRISPR-Cas9 gene editing technology has potential to transform the field of gene therapy through its simple and cost-effective delivery mechanism, said...

NOS PROCHAINES FORMATIONS